Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday

Indaptus Therapeutics (NASDAQ:INDP) is expected to be issuing its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($4.36) per share for the quarter.

Indaptus Therapeutics Stock Up 6.9%

INDP opened at $2.01 on Thursday. The firm has a market cap of $4.50 million, a P/E ratio of -0.06 and a beta of 0.97. Indaptus Therapeutics has a 52 week low of $1.52 and a 52 week high of $47.60. The business has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $3.04.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors own 7.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wall Street Zen cut shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics presently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.